The DNMT inhibitors, 5-azacytidine (5-aza) and its structural analogue, 5-aza-2’-deoxycytidine (5-AzaD), have been approved for treatment of myelodysplastic syndrome. This evidence concerns the gene DNMT1 and myelodysplastic syndrome.